Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy

References

• Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3–12.
   PubMed Web of Science ®Google Scholar
• Brooke GN, Parker MG, Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 2008;27:2941–50.
   Google Scholar
• Kojima S, Suzuki S, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171:679–83.
   PubMed Web of Science ®Google Scholar
• Buchana G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273–81.
   Google Scholar
• Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000;164:1992–5.
   PubMed Web of Science ®Google Scholar
• Hirano D, Jike T, Okada Y, Minei S, Sugimoto S, Yamaguchi K, et al. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study. Ultrastruct Pathol 2005;29:367–75.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine–paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91–8.
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298–307.
   PubMed Web of Science ®Google Scholar
• di Sant'Agnese PA, de Mesy Jensen KL. Somatostatin and/or somatostatin-like immunoreactive endocrine–paracrine cells in the human prostate gland. Arch Pathol Lab Med 1984;108:693–6.
   PubMed Web of Science ®Google Scholar
• Iwamura M, Wu G, Abrahamsson PA, di Sant'Agnese P, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994;43:667–74.
   PubMed Web of Science ®Google Scholar
• Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:587–92.
   Google Scholar
• Hirano D, Minei S, Sugimoto S, Yamaguchi K, Yoshikawa T, Hachiya T, et al. Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol 2007;41:297–301.
   PubMed Web of Science ®Google Scholar
• Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252–8.
   PubMed Web of Science ®Google Scholar
• Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461–7.
   PubMed Web of Science ®Google Scholar
• Appetecchia M, Mecule A, Pasimeni G, V lannucci C, De Carli P, Baldelli R, et al. Incidence of high chromogranin A serum levels in patients with non-metastatic prostate adenocarcinoma. J Exp Clin Cancer Res 2010;29:166–71.
   PubMedGoogle Scholar
• DiLorenzo G, Buonerba C, Autorino R, DePlacido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010;70:983–1000.
   Google Scholar
• Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995;154:448–53.
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96:791–5.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921–7.
   PubMed Web of Science ®Google Scholar
• Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007;14:128–32.
   PubMed Web of Science ®Google Scholar
• di Sant's Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001;12:S135–40.
   Google Scholar
• Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147–55.
   PubMed Web of Science ®Google Scholar
• Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340–3.
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590–7.
   PubMed Web of Science ®Google Scholar
• Ishiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512–15.
   Google Scholar
• Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997;31:110–17.
   PubMed Web of Science ®Google Scholar
• Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109–17.
   Web of Science ®Google Scholar
• Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844–8.
   PubMedGoogle Scholar
• Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003;55:168–79.
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33–9.
   PubMed Web of Science ®Google Scholar
• Culig Z. Androgen receptor cross-talk with cell signaling pathway. Growth Factors 2004;22:179–84.
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276–308.
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946–51.
   PubMed Web of Science ®Google Scholar